Bright Minds Biosciences Inc.

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies

Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on